What’s Behind the 165% Surge in Carisma Therapeutics Stock (CARM) Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Source: TipRanks
Merger Update: Carisma Therapeutics' stock surged 164.6% after announcing a merger with Ocugen's subsidiary OrthoCellix, which includes agreements for up to $30 million in gross proceeds from investors and Ocugen.
Leadership and Stock Performance: CEO Steven Kelly will continue post-merger with stock options and bonuses contingent on the deal's completion, while the stock remains down 48.81% year-to-date, with Wall Street coverage being limited.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
